7.8 C
London
Monday, November 18, 2024
HomeUncategorizedCentre takes steps to accelerate domestic vaccine production

Centre takes steps to accelerate domestic vaccine production

Date:

Related stories

Meteo: prima tempesta stagionale, venti forti su metà Italia

Il meteo e l’arrivo dell’autunno in Europa L’autunno sta per...

Meteo: due giorni di freddo intenso in settimana, possibile neve?

Condizioni meteorologiche iniziali della‌ settimana La ​settimana si‌ apre con...

Il meteo della prossima settimana sarà sorprendente

Un cambiamento radicale nel meteo ‌è ⁢alle porte Non​ è...

Novembre al mare: il clima non dimentica questo disastro

Un Novembre insolito: sole e bagnanti al posto delle...

Ministry of Science & Technology

Centre takes steps to accelerate domestic vaccine production



Haffkine Biopharma to produce 22.8 crore doses per annum of Covaxin under technology transfer arrangement with Bharat Biotech

Posted On:
02 JUN 2021 11:10AM by PIB Mumbai

Mumbai | June 2,  2021

With the aim of vaccinating the entire eligible population at the earliest, domestic vaccine production is being steadily ramped up in the country with help from the Centre.   

As part of this initiative, three public enterprises are being supported by  the Department of Biotechnology under Atmanirbhar Bharat 3.0  Mission Covid Suraksha.  These enterprises are the 

1. Haffkine Biopharmaceutical Corporation Ltd, Mumbai,  

2. Indian Immunologicals Ltd, Hyderabad and 

3. Bharat Immunologicals & Biologicals Ltd, Bulandshahar, UP.

Haffkine Biopharma, a Maharashtra state PSU is getting ready to manufacture Covaxin vaccine under technology transfer arrangement with Bharat Biotech Ltd, Hyderabad.  The production will take place at the Parel complex of the company. 

Dr. Sandeep Rathod, Managing Director of Haffkine BioPharma said the company proposes to produce 22.8 crore doses of Covaxin in a year.  “For undertaking production of Covaxin, Haffkine Biopharma has been provided with Rs 65 crore grant by the Centre and Rs 94 crore from the Government of Maharashtra” he added. 

 “We have been given a timeline of eight months and the work is being executed on a war footing. The vaccine production process involves two stages – drug substance and final drug product.  For production of drug substance we need to build a Bio Safety Level 3 (BSL 3) facility, while Haffkine already has the Fill Finish facility” said Rathod, the doctor turned IAS officer.  BSL 3 is a safety standard applicable to such facilities where work involves microbes which can cause serious disease via inhalation route. 

‘Enhancing vaccine production capacity using Public sectors assets will go a long way in building production capacity of vaccines in our country to support the massive vaccination drive” said, Dr Renu Swarup,  Secretary Department of Biotechnology and Chairperson BIRAC (Biotechnology Industry Research Assistance Council )

Haffkine BioPharmaceutical Corporation Ltd is an offshoot of the 122 year old Haffkine Institute, which is one of the oldest biomedical research institutes in the country, named after the Russian  bacteriologist Dr. Waldemar Haffkine, who invented the plague vaccine. 

Sources : 

• Department of Biotechnology background note. 

• Interview with Dr. Sandeep Rathod, MD, Haffkine Biopharma, Mumbai

Message for TV News Channels / YouTube channels.

Haffkine Biopharma video feed available through ANI

***

PIB Mum | MD/RT/JPS/AS/DY

सोशल मिडियावर आम्हाला फॉलो करा: @PIBMumbai   Image result for facebook icon /PIBMumbai    /pibmumbai  pibmumbai@gmail.com

(Release ID: 1723608)
Visitor Counter : 11




Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories